TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16122587

Group type: EXPERIMENTAL
Intervention: Partner Violence Screen (PVS) with injury location
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: short-Woman Abuse Screening Tool (short-WAST) with injury location
Number of subjects: 200
Study: 12697080

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 1558
Study: 10657535

Group type: EXPERIMENTAL
Intervention: TRH test during cocaine withdrawal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TRH test after 30 days of cocaine abstinence
Number of subjects: 26
Study: 8527287

Group type: EXPERIMENTAL
Intervention: Tolcapone (10-800 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 1453728

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard perfusion (NP)
Number of subjects: 100
Study: 6230173

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg bid for 14 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 10
Study: 30835822

Group type: EXPERIMENTAL
Intervention: Intra-operative dexmedetomidine (0.5 µg.kg-1 bolus followed by 0.4 µg.kg-1.hr-1 infusion)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study: 30701937

Group type: EXPERIMENTAL
Intervention: Standard triple therapy (omeprazole, amoxicillin, clarithromycin)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Four-component therapy with bismuth (omeprazole, tetracycline, metronidazole, bismuth tricalium dicitrate)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Hybrid scheme (first 5 days: omeprazole and amoxicillin, next 5 days: omeprazole, amoxicillin, clarithromycin, metronidazole)
Number of subjects: 180
Study: 26809143

Group type: EXPERIMENTAL
Intervention: Familiar vegetable (carrot)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Novel vegetable (celeriac)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 95
Study: 23548526

Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg single dose)
Number of subjects: 179
Study: 22232815

Group type: EXPERIMENTAL
Intervention: Percutaneous reduction (PR) and calcium sulfate cement (CSC) grafting
Number of subjects: 90

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Percutaneous reduction (PR)
Number of subjects: 90
Study: 19230758

Group type: EXPERIMENTAL
Intervention: Algorithm-calculated CPAP pressure (mean 7.0 cmH2O)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Auto-CPAP titration (optimal pressure 7.0 cmH2O)
Number of subjects: 69
Study: 16319211

Group type: EXPERIMENTAL
Intervention: Visual stimuli visible only to short‐wave‐sensitive cones (S cones)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Luminance pathways
Number of subjects: 0
Study: 14604599

Group type: EXPERIMENTAL
Intervention: Early shift (awakening: 04:00-05:30 h)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Late shift (awakening: 06:00-09:00 h)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Night shift (awakening: 11:00-14:00 h)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Students after short nap (awakening: 18:45-20:30 h)
Number of subjects: 55
Study: 11770253

Group type: EXPERIMENTAL
Intervention: Opiate maintenance program
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 175
Study: 9167026

Group type: EXPERIMENTAL
Intervention: Neutrophil autoantibodies (ANCA) detection in patients with IBD
Number of subjects: 500
Study: 1540729

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 40
Study: 3873834

Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 40

Group type: COMPARATOR
Intervention: Renografin-60
Number of subjects: 40
Study: 29376434

Group type: EXPERIMENTAL
Intervention: Aerobic, resistive, and Tai Chi exercise for 8 weeks to 12 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physical activity (non-interventional studies)
Number of subjects: 16
Study: 29016275

Group type: COMPARATOR
Intervention: Combined Behavioral Intervention (CBI)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Psychoanalytic-Interactional Therapy (PIT)
Number of subjects: 215
Study: 27134145

Group type: EXPERIMENTAL
Intervention: Concomitant treatment (esomeprazole 40mg, amoxicillin 1g/bid for 5 days, followed by 5 days of esomeprazole 40mg, clarithromycin 500mg and metronidazole 500mg bid for 10 days)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Sequential treatment (same drugs as concomitant but taken sequentially)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Concomitant treatment
Number of subjects: 353

Group type: COMPARATOR
Intervention: Sequential treatment
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 353
Study: 25352299

Group type: EXPERIMENTAL
Intervention: Combined Diet Dialysis Program (CDDP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard thrice-a-week hemodialysis (THD)
Number of subjects: 68
Study: 22503778

Group type: EXPERIMENTAL
Intervention: Visual feedback group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Auditory feedback group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Removal of feedback
Number of subjects: 2
Study: 20198405

Group type: EXPERIMENTAL
Intervention: Cemented Charnley cup
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Uncemented Duraloc 1200 cup
Number of subjects: 215

Group type: COMPARATOR
Intervention: Cemented Charnley cup and Uncemented Duraloc 1200 cup
Number of subjects: 215
Study: 19094439

Group type: EXPERIMENTAL
Intervention: Cefuroxime-sulbactam
Number of subjects: 75

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 75
Study: 16213401

Group type: EXPERIMENTAL
Intervention: Occlusive patching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Driving monocularly (with patching)
Number of subjects: 30
Study: 11801507

Group type: EXPERIMENTAL
Intervention: Scanning laser polarimeter (GDx; GDx Nerve Fiber Analyzer)
Number of subjects: 184
Study: 10078856

Group type: EXPERIMENTAL
Intervention: 2% aminophylline cream (AC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: no cream (NC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo cream (PC)
Number of subjects: 9
Study: 7484326

Group type: EXPERIMENTAL
Intervention: Binge-prone group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Binge-prone women in the presence of food they enjoyed
Number of subjects: 126
Study: 2397758

Group type: EXPERIMENTAL
Intervention: Increased inertial load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased inertial load
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no unexpected load change)
Number of subjects: 0
Study: 434004

Group type: EXPERIMENTAL
Intervention: Crystalline arborization test
Number of subjects: 25

Group type: COMPARATOR
Intervention: Urine samples
Number of subjects: 25
Study: 30429415

Group type: EXPERIMENTAL
Intervention: Gefitinib plus bevacizumab (GEF+BEV group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gefitinib (GEF group)
Number of subjects: 0
Study: 28335664

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy intervention (CBTi)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Telephone Counseling (TC)
Number of subjects: 84
Study: 25599147

Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents
Number of subjects: 17
Study: 23456540

Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) Course
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study: 21832111

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Combined (Clomiphene citrate + Metformin)
Number of subjects: 626
Study: 19602916

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 17357903

Group type: EXPERIMENTAL
Intervention: Pneumatic compression (FemoStop system)
Number of subjects: 2085

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 2085
Study: 15289792

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg)
Number of subjects: 13
Study: 11715169

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (0.5 mL containing A/Wuhan/359/95 (H3N2), A/Texas/36/91 (H1N1), B/Beijing/184/93)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 493
Study: 9570259

Group type: EXPERIMENTAL
Intervention: 15 or 30 mg lansoprazole/day
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole/day
Number of subjects: 111
Study: 8056998

Group type: EXPERIMENTAL
Intervention: lorazepam 0.5 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: lorazepam 0.75 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: lorazepam 1 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: lorazepam up to 1.5 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study: 3383875

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d. (n = 154)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo (n = 147)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 31127676

Group type: EXPERIMENTAL
Intervention: Folic acid 0.8 mg daily for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 0
Study: 31786810

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 2226

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 2226

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 2226

Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 2226

Group type: EXPERIMENTAL
Intervention: Procaine
Number of subjects: 2226

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 2226

Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine
Number of subjects: 2226

Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 2226
Study: 28715540

Group type: EXPERIMENTAL
Intervention: Pyridoxine (200 mg daily for a maximum of 8 cycles of capecitabine)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (daily for a maximum of 8 cycles of capecitabine)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Pyridoxine and Placebo (both arms)
Number of subjects: 210
Study: 25137370

Group type: EXPERIMENTAL
Intervention: Interval training group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 24026257

Group type: EXPERIMENTAL
Intervention: Home-based intervention delivered by social workers
Number of subjects: 208

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 208
Study: 20185003

Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine response (10 microg/kg/min)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Microvascular obstruction (MVO)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Relative delayed enhancement extent (DE)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Transmural DE pattern (TMDE)
Number of subjects: 69
Study: 18388122

Group type: EXPERIMENTAL
Intervention: Calcium Carbonate (CC) 500 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sevelamer Hydrochloride (SEV) 800 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15898218

Group type: EXPERIMENTAL
Intervention: Automated system with recommendation to prescribe angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control group with no recommendation
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Automated system with recommendation to prescribe statins
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control group with no recommendation for statins
Number of subjects: 4000
Study: 12534414

Group type: EXPERIMENTAL
Intervention: Alosetron (1 mg b.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (b.d.)
Number of subjects: 15
Study: 10368502

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microgram intravaginally every 4 hours)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Prepidil (0.5 mg intracervically every 6 hours)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 159

Group type: COMPARATOR
Intervention: Prepidil
Number of subjects: 159
Study: 8905421

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aerosolized prostacyclin
Number of subjects: 16
Study: 1702812

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day for 3 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 9
Study: 6276584

Group type: EXPERIMENTAL
Intervention: β-endorphin 2 mg intrathecally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: morphine HCl 0.2 mg intrathecally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (halothane-N2O anesthesia)
Number of subjects: 20
Study: 31449470

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with cisplatin and gemcitabine followed by standard chemoradiation (CRT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard chemoradiation (CRT) alone
Number of subjects: 107
Study: 28543873

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 191
Study: 26341118

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 23715821

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2 % cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pimecrolimus 1 % cream
Number of subjects: 60
Study: 22832429

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 8 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Post-mortem brain samples from MDD subjects
Number of subjects: 63
Study: 20008582

Group type: EXPERIMENTAL
Intervention: Anticipatory and Preventive Team Care (APTCare)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care from family physicians
Number of subjects: 241
Study: 16923461

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clopidogrel 900 mg loading dose
Number of subjects: 45

Group type: COMPARATOR
Intervention: Clopidogrel 300 mg loading dose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clopidogrel cessation
Number of subjects: 45
Study: 12908110

Group type: EXPERIMENTAL
Intervention: Two embryos (Group 1)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Three embryos (Group 2)
Number of subjects: 169
Study: 11521332

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid, lipid-lowering drugs, vitamins, and exercise (primary preventive effects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reducing triglyceride levels or abdominal obesity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angina as a non-specific symptom
Number of subjects: 0
Study: 9072600

Group type: EXPERIMENTAL
Intervention: Double freeze-thaw cycle
Number of subjects: 150

Group type: COMPARATOR
Intervention: Single freeze-thaw cycle
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Salvage cryotherapy (overall)
Number of subjects: 150
Study: 8430362

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy after curative resection (CR + R)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy after palliative resection (PR + R)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (CR + R and PR + R)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group after curative resection (CR)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group after palliative resection (PR)
Number of subjects: 130
Study: 2888072

Group type: EXPERIMENTAL
Intervention: Educational program intervention
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 403
Study: 31751758

Group type: EXPERIMENTAL
Intervention: Routine laboratory screening for secondary causes of CSU
Number of subjects: 0

Group type: COMPARATOR
Intervention: No testing approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihistamine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclospirine therapy
Number of subjects: 0
Study: 28941141

Group type: EXPERIMENTAL
Intervention: 600 mg of ortho-silicic acid stabilized by hydrolyzed collagen (group 1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 22
Study: 27207965

Group type: EXPERIMENTAL
Intervention: Rapid uptitration protocol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prolonged uptitration protocol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 46
Study: 25030264

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study: 22944873

Group type: EXPERIMENTAL
Intervention: Early integrated treatment group (ART within 4 weeks of tuberculosis treatment initiation)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Late integrated treatment group (ART within 4 weeks of completion of the intensive phase of tuberculosis treatment)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Sequential treatment group (ART within 4 weeks after tuberculosis therapy completion)
Number of subjects: 642
Study: 20090313

Group type: EXPERIMENTAL
Intervention: Pullulan (12 g/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Promitor Resistant Starch (12 g/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Soluble fiber dextrin (12 g/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Promitor Soluble Corn Fiber (12 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All fibers (12 g/day)
Number of subjects: 20
Study: 17255841

Group type: EXPERIMENTAL
Intervention: Rice-based ORS plus lactoferrin and lysozyme (Lf/Lz-R-ORS)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Low osmolarity WHO-ORS (G-ORS) and rice-based ORS (R-ORS) combined as control
Number of subjects: 140
Study: 15377472

Group type: COMPARATOR
Intervention: CHOP chemotherapy
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: CHOP + G-CSF
Number of subjects: 411
Study: 11702619

Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide plus 1% clindamycin
Number of subjects: 480

Group type: COMPARATOR
Intervention: 5% benzoyl peroxide
Number of subjects: 480

Group type: COMPARATOR
Intervention: 1% clindamycin
Number of subjects: 480

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 480
Study: 9590570

Group type: EXPERIMENTAL
Intervention: Captopril (25-100 mg daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Atenolol (50-100 mg daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Captopril and Atenolol
Number of subjects: 37
Study: 7931870

Group type: EXPERIMENTAL
Intervention: Intervention schools (labeled low-fat entrees on menus and parent notification)
Number of subjects: 2445

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 2445

Group type: EXPERIMENTAL
Intervention: Parents surveyed after intervention
Number of subjects: 2445
Study: 3281774

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Codeine (120 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31339789

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV) information and education
Number of subjects: 4430

Group type: EXPERIMENTAL
Intervention: Junior college degree
Number of subjects: 4430

Group type: EXPERIMENTAL
Intervention: Higher influenza knowledge level (medium level)
Number of subjects: 4430

Group type: EXPERIMENTAL
Intervention: Higher influenza knowledge level (high level)
Number of subjects: 4430

Group type: EXPERIMENTAL
Intervention: Previous influenza information
Number of subjects: 4430

Group type: COMPARATOR
Intervention: No previous QIV-related information
Number of subjects: 4430

Group type: COMPARATOR
Intervention: No perceived susceptibility of children to influenza
Number of subjects: 4430

Group type: COMPARATOR
Intervention: Fear of side effects
Number of subjects: 4430

Group type: COMPARATOR
Intervention: Concern that vaccines need to be carefully administered
Number of subjects: 4430

Group type: COMPARATOR
Intervention: Mistrust of new vaccines
Number of subjects: 4430
Study: 30213012

Group type: EXPERIMENTAL
Intervention: High-dose IFNα‐2b (9 million IU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of high-dose IFNα‐2b and red light therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low-dose recombinant IFNα‐2b (1 million IU)
Number of subjects: 90
Study: 27761471

Group type: EXPERIMENTAL
Intervention: Activity monitor
Number of subjects: 187

Group type: COMPARATOR
Intervention: Pedometer
Number of subjects: 187
Study: 24656288

Group type: EXPERIMENTAL
Intervention: Sitaxentan 50 mg
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Sitaxentan 100 mg
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246